OBJECTIVE: To characterize longitudinal changes in blood biomarkers, leukocyte composition, and gene expression following laparoscopic sleeve gastrectomy (LSG). BACKGROUND: LSG is an effective treatment for obesity, leading to sustainable weight loss and improvements in obesity-related comorbidities and inflammatory profiles. However, the effects of LSG on immune function and metabolism remain uncertain. METHODS: Prospective data were collected from 23 enrolled human subjects from a single institution. Parameters of weight, comorbidities, and trends in blood biomarkers and leukocyte subsets were observed from preoperative baseline to 1 year postsurgery in 3-month follow-up intervals. RNA sequencing was performed on pairs of whole blood samples from the first 6 subjects of the study (baseline and 3 months postsurgery) to identify genome-wide gene expression changes associated with undergoing LSG. RESULTS: LSG led to a significant decrease in mean total body weight loss (18.1%) at 3 months and among diabetic subjects a reduction in hemoglobin A1c. Improvements in clinical inflammatory and hormonal biomarkers were demonstrated as early as 3 months after LSG. A reduction in neutrophil-lymphocyte ratio was observed, driven by a reduction in absolute neutrophil counts. Gene set enrichment analyses of differential whole blood gene expression demonstrated that after 3 months LSG induced transcriptomic changes not only in inflammatory cytokine pathways but also in several key metabolic pathways related to energy metabolism. CONCLUSIONS: LSG induces significant changes in the composition and metabolism of immune cells as early as 3 months postoperatively. Further evaluation is required of bariatric surgery's effects on immunometabolism and the consequences for host defense and metabolic disease.
OBJECTIVE: To characterize longitudinal changes in blood biomarkers, leukocyte composition, and gene expression following laparoscopic sleeve gastrectomy (LSG). BACKGROUND: LSG is an effective treatment for obesity, leading to sustainable weight loss and improvements in obesity-related comorbidities and inflammatory profiles. However, the effects of LSG on immune function and metabolism remain uncertain. METHODS: Prospective data were collected from 23 enrolled human subjects from a single institution. Parameters of weight, comorbidities, and trends in blood biomarkers and leukocyte subsets were observed from preoperative baseline to 1 year postsurgery in 3-month follow-up intervals. RNA sequencing was performed on pairs of whole blood samples from the first 6 subjects of the study (baseline and 3 months postsurgery) to identify genome-wide gene expression changes associated with undergoing LSG. RESULTS: LSG led to a significant decrease in mean total body weight loss (18.1%) at 3 months and among diabetic subjects a reduction in hemoglobin A1c. Improvements in clinical inflammatory and hormonal biomarkers were demonstrated as early as 3 months after LSG. A reduction in neutrophil-lymphocyte ratio was observed, driven by a reduction in absolute neutrophil counts. Gene set enrichment analyses of differential whole blood gene expression demonstrated that after 3 months LSG induced transcriptomic changes not only in inflammatory cytokine pathways but also in several key metabolic pathways related to energy metabolism. CONCLUSIONS: LSG induces significant changes in the composition and metabolism of immune cells as early as 3 months postoperatively. Further evaluation is required of bariatric surgery's effects on immunometabolism and the consequences for host defense and metabolic disease.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Tammy Lo; Renuka S Haridas; Eleanor J M Rudge; Robert P Chase; Keyvan Heshmati; Elizabeth M Lucey; Alison M Weigl; Otatade J Iyoha-Bello; Chelsea O Ituah; Emily J Benjamin; Seth W McNutt; Leena Sathe; Leanna Farnam; Benjamin A Raby; Ali Tavakkoli; Damien C Croteau-Chonka; Eric G Sheu Journal: J Clin Endocrinol Metab Date: 2022-01-18 Impact factor: 6.134
Authors: Stuart P Weisberg; Daniel McCann; Manisha Desai; Michael Rosenbaum; Rudolph L Leibel; Anthony W Ferrante Journal: J Clin Invest Date: 2003-12 Impact factor: 14.808
Authors: Fahim Abbasi; James W Chu; Cindy Lamendola; Tracey McLaughlin; John Hayden; Gerald M Reaven; Peter D Reaven Journal: Diabetes Date: 2004-03 Impact factor: 9.461
Authors: David A Harris; Amir Mina; Dimitrije Cabarkapa; Keyvan Heshmati; Renuka Subramaniam; Alexander S Banks; Ali Tavakkoli; Eric G Sheu Journal: Am J Physiol Endocrinol Metab Date: 2020-02-18 Impact factor: 4.310
Authors: Tammy Lo; Renuka S Haridas; Eleanor J M Rudge; Robert P Chase; Keyvan Heshmati; Elizabeth M Lucey; Alison M Weigl; Otatade J Iyoha-Bello; Chelsea O Ituah; Emily J Benjamin; Seth W McNutt; Leena Sathe; Leanna Farnam; Benjamin A Raby; Ali Tavakkoli; Damien C Croteau-Chonka; Eric G Sheu Journal: J Clin Endocrinol Metab Date: 2022-01-18 Impact factor: 6.134